Invest in Hera Diagnostics
Hera Diagnostics saves lives by delivering cervical cancer screening to the global community
Pitch Video
Investor Panel
Highlights
1
Over 300,000 women die annually from cervical cancer even though the disease is easily treatable
2
90% of cervical cancer deaths occur in underserved populations globally
3
Hera will reduce those deaths by delivering high-tech screening to low-tech communities
4
Our device is portable, accurate, affordable, painless and gives real time, point-of-care results
Featured Investor
Invested $150,000
Invested $25,000 this round & $125,000 previously
“Encore Health is proud to collaborate with Hera Diagnostics, sharing the same vision of developing cost effective technology that revolutionizes cancer screening procedures, for the sake of improving health. We also share with Hera the social commitment to contribute to the medical community, providing practical solutions that facilitate the prevention and care of cancerous diseases.We´re excited to start this new project with a company like Hera Diagnostics and with its team of valuable prof...”
Our Team
CEO
Bilingual Spanish/English well-rounded executive with a career trajectory that spans organizational leadership, business development, marketing,
corporate management, entrepreneurship, manufacturing, and innovation.
Cervical cancer is a leading cause of death from cancer among women in developing countries. Hera Diagnostics technology was developed to address this crisis through reliable, affordable and immediate screening technology.
COO & General Counsel
Delaney’s career background and experience is varied in a multitude of areas including law, business
development, operations, HR, tech, and healthcare. As a result she excels in hybrid positions that encompass legal and strategy responsibilities.
Jesus SeanezChief Technology Officer
As a biomedical engineer, Jesus has the fundamental knowledge to launch the integration of existing technologies, as well as launch those that need to be improved and those that are yet to be created.
